New asthma drug enters early human safety testing
NCT ID NCT07330778
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This early-stage study tests a single dose of an experimental drug called CDX-622 in 12 adults with mild to moderate asthma. The main goal is to see if the drug is safe and to measure how it affects markers of airway inflammation. Participants will be monitored for side effects and changes in breathing over 12 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD TO MODERATE ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
-
The University of Kansas Medical Center
RECRUITINGKansas City, Kansas, 66160, United States
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
-
University of Pittsburgh Asthma and Environmental Lung Health Institute at UPMC
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.